This product is analyzed for solubility in DMSO on a lot to lot basis. The specification is: ≥ 20.0 mg/mL. Kindly review the lot specific certificate of analysis for the resulting maximum solubility of the lot received.
SML0800
Rimonabant hydrochloride
≥98% (HPLC), powder, cannabinoid type-I receptor antagonist
Sinónimos:
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide hydrochloride, SR-141716, SR-141716A, SR141716, SR141716A
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Seleccione un Tamaño
5 MG
MXP 1,865.00
25 MG
MXP 9,557.00
Seleccione un Tamaño
Cambiar Vistas
5 MG
MXP 1,865.00
25 MG
MXP 9,557.00
About This Item
Fórmula empírica (notación de Hill):
C22H21Cl3N4O · HCl
Número de CAS:
Peso molecular:
500.25
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77
Productos recomendados
Nombre del producto
Rimonabant hydrochloride, ≥98% (HPLC)
Ensayo
≥98% (HPLC)
Formulario
powder
condiciones de almacenamiento
desiccated
color
white to beige
solubilidad
DMSO: 20 mg/mL, clear
temp. de almacenamiento
2-8°C
cadena SMILES
CC1=C(C2=CC=C(Cl)C=C2)N(C3=CC=C(Cl)C=C3Cl)N=C1C(NN4CCCCC4)=O.Cl
InChI
1S/C22H21Cl3N4O.ClH/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15;/h5-10,13H,2-4,11-12H2,1H3,(H,27,30);1H
Clave InChI
REOYOKXLUFHOBV-UHFFFAOYSA-N
Información sobre el gen
human ... CNR1(1268)
Aplicación
Rimonabant hydrochloride has been used as an antagonist of cannabinoid 1 (CB1) receptor:
- to study its effects on protein synthesis in C2C12 myotubes[1]
- to analyze its effects on human astroglia[2]
- in combination with methanandamide (mAEA) to study its effects on murine gastric vagal afferent mechanosensitivity[3]
Acciones bioquímicas o fisiológicas
Rimonabant acts as a mycobacterial membrane protein large 3 (MMPL3) inhibitor.[4] Rimonabant hydrochloride exhibits therapeutic activity against weight reduction and smoking cessation.[5]
Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
Rimonabant hydrochloride (SR-141716A) is a potent and selecvtive CB1 cannabinoid inverse agonist/antagonist with some GPR55 agonist activity and an appetite suppressant.
Características y beneficios
This compound is featured on the Cannabinoid Receptors and Cannabinoid Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Palabra de señalización
Danger
Frases de peligro
Consejos de prudencia
Clasificaciones de peligro
Acute Tox. 3 Oral - Eye Irrit. 2
Código de clase de almacenamiento
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
¿No ve la versión correcta?
Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
A novel validated RP-HPLC method development for the estimation of rimonabant hydrochloride in bulk and tablet dosage forms
Nama S, et al.
African Journal of Pharmacy and Pharmacology, 5(2), 207-213 (2011)
Jorge Emilio Ortega et al.
European journal of pharmacology, 709(1-3), 13-19 (2013-04-09)
Current pharmacological therapies for depression, including selective serotonin reuptake inhibitors (SSRI), are far from ideal. The cannabinoid system has been implicated in control of mood and neural processing of emotional information, and the modulation of serotonin (5-HT) release in the
Marc-Antoine Perrin et al.
Journal of pharmaceutical sciences, 102(7), 2311-2321 (2013-05-23)
Crystalline polymorphism occurs frequently in the solid state of active pharmaceutical ingredients, and this is problematic for the development of a suitable dose form. Rimonabant, an active pharmaceutical ingredient developed by Sanofi and discontinued because of side effects, exhibits dimorphism;
Wei Chen et al.
Naunyn-Schmiedeberg's archives of pharmacology, 386(8), 721-732 (2013-04-27)
Effects of cannabinoid receptor 1 (CB1R) blockade were observed by comparing 9-day and 6-week SR141716 treatments in monosodium glutamate (MSG)-induced hypometabolic and hypothalamic obesity (HO) in rats for the first time and molecular mechanisms were investigated. Compared with normal rats
Svetlana Slavic et al.
Journal of molecular medicine (Berlin, Germany), 91(7), 811-823 (2013-05-03)
The cannabinoid receptors, CB1 and CB2, are expressed in the heart, but their role under pathological conditions remains controversial. This study examined the effect of CB1 receptor blockade on cardiovascular functions after experimental MI and in experimental metabolic syndrome. MI
Artículos
We offer many products related to cannabinoid receptors for your research needs.
-
Hi ! In the product information its marked that rimonabant's solubility in DMSO is "20 mg/mL, clear". Is it its maximum solubility in DMSO?
1 answer-
Helpful?
-
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
